BridgeMD
PAROCAINE : Evaluation of the Clinical Tolerance of an Intra-Parotid Injection of Bupivacaine Combined with Dexamethasone After Parotidectomy for a Benign Tumor – Prospective Single-Center Cohort Study
EU CTIS ID: 2025-524358-32-00
What this study is testing
To evaluate the clinical tolerance (safety, adverse effects) of an injection of a mixture of bupivacaine (100 mg) and dexamethasone (2 mg) into parotid tissue up to 15 days after partial parotidectomy for a benign tumor.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Validated surgical indication for partial parotidectomy for parotid tumor.
- Age ≥ 18 years
- For patients of childbearing age, active contraception method.
- Person affiliated with or beneficiary of a social security system.
You likely can't join if
- History of allergic reaction to aminoamide local anesthetics.
- Severe neurological history (epilepsy, peripheral neuropathies).
- History of cardiovascular risk factors (severe hypertension, arrhythmias, complete or incomplete heart block, heart failure, coronary artery disease, treatment with type 2 antiarrhythmic drugs).
- Severe liver or kidney disease (severe liver or kidney failure).
- Acidosis, sepsis.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.